Drugs / felcisetrag
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03870555 | Mar → May 2019 | — | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03500224 | Apr → Jun 2018 | — | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03296787 | Nov 2017 → Aug 2019 | impaired renal function disease | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03277274 | Nov 2017 → Sep 2018 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03173170 | May → Jul 2017 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01644240 | Sep → Nov 2012 | intestinal motility disease | Theravance Biopharma | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01953081 | Jan → Sep 2014 | food protein-induced enterocolitis syndrome | Takeda | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT03827655 | Mar 2019 → May 2022 | intestinal dysmotility syndrome | Takeda | Completed | Missed primary |
| Phase 2 | NCT03477903 | Aug 2018 | — | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03281577 | Jan 2018 → Jun 2019 | idiopathic gastroparesis | Takeda | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-06-08 | Takeda | Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders takeda.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | felcisetrag | “The 5-hydroxytryptamine type-4 receptor agonist felcisetrag (TAK-954) is being investigated for improving gastrointestinal motility in postoperative gastrointestinal dysfunction.” PMID 34989180 ↗ Jan 2022 |
| Known as | TAK-954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03477903 ↗ |
| Known as | TD-8954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01644240 ↗ |
| Known as | THRX-149699 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2402904 ↗ |
| Action | Activate | “Serotonin 4 (5-HT4) receptor agonist” CHEMBL2402904 ↗1“a 5-HT4 Receptor Agonist” NCT01644240 ↗ |
| Modality | Small molecule | — CHEMBL2402904 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT01644240 ↗ |
| Target | HTR4 | “Serotonin 4 (5-HT4) receptor agonist” CHEMBL2402904 ↗ |